Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 5:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1897–1920 of 2,465 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Ovarian Tumors Clear all
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Effect of 'Cramp Bites' on Period Cramps in Women Aged 18-25

NCT06227676
View directory record Official record
Conditions
Dysmenorrhea Primary, Dysmenorrhea, Menstrual Discomfort, Menstrual Problem, Menstrual Cycle Abnormal, Menstrual Pain, Period Pain, Period Problem, PMS, Premenstrual Syndrome, PCOS, PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, PCOS (Polycystic Ovary Syndrome) of Left Ovary, PCOS (Polycystic Ovary Syndrome) of Right Ovary, Polycystic Ovary Syndrome, Premenstrual Dysphoric Disorder, Cramps, Ovarian Cysts
Interventions
Cramp Bites by Aunt Flo's Kitchen
Dietary Supplement
Lead sponsor
Cornell University
Other
Eligibility
18 Years to 25 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Ithaca, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2024 · Synced Oct 29, 2026, 5:04 AM EDT
Active, not recruiting Not applicable Interventional Results available

Screening for Ovarian Cancer in Older Patients (PLCO Screening Trial)

NCT01696994
View directory record Official record
Conditions
Ovarian Carcinoma, Ovarian Germ Cell Tumor
Interventions
Laboratory Biomarker Analysis, Screening Questionnaire Administration, Ultrasound Imaging
Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
55 Years to 74 Years · Female only
Enrollment
78,216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 29, 2026, 5:04 AM EDT
Completed Phase 1 Interventional Results available

A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors

NCT02573259
View directory record Official record
Conditions
Part 1, MELANOMA, SCCHN, OVCA, SARCOMA, OTHER SOLID TUMORS, Part 1 and 2, NSCLC, UROTHELIAL CARCINOMA
Interventions
PF-06801591
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
24
States / cities
Los Angeles, California • Santa Monica, California • Louisville, Kentucky + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Oct 29, 2026, 5:04 AM EDT
Completed Phase 1Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Germ Cell Tumors That Have Not Responded to Previous Cisplatin

NCT00002559
View directory record Official record
Conditions
Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
filgrastim, cisplatin, ifosfamide, paclitaxel
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
15 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 2, 2013 · Synced Oct 29, 2026, 5:04 AM EDT
Completed Phase 2 Interventional Results available

Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT00267696
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
Bevacizumab, Gemcitabine, Carboplatin
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 29, 2026, 5:04 AM EDT
Completed Phase 2 Interventional Results available

Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

NCT01078662
View directory record Official record
Conditions
Ovarian, Breast, Prostate, Pancreatic, Advanced Tumours
Interventions
olaparib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2024
U.S. locations
2
States / cities
West Hollywood, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Oct 29, 2026, 5:04 AM EDT
Terminated Not applicable Interventional Results available

Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan

NCT00720096
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Liposomal Doxorubicin, Topotecan
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 2, 2018 · Synced Oct 29, 2026, 5:04 AM EDT
Recruiting Phase 2 Interventional

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

NCT06503146
View directory record Official record
Conditions
Sarcoma, Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC), Mesothelioma, Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Ductal Adenocarcinoma, Ovarian Cancer, Hepatocellular Carcinoma, Gastric Cancer, Cholangiocarcinoma, Bladder Cancer
Interventions
[18F]FAPI-74, [18F]FDG
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 29, 2026, 5:04 AM EDT
Completed Not applicable Interventional

Effects of a Teaching Intervention With an Advanced Practice Nurse on Quality of Life and Psychosocial and Symptom Distress in Patients With Ovarian Cancer

NCT00900679
View directory record Official record
Conditions
Ovarian Cancer, Transitional Care Planning
Interventions
telephone-based intervention, counseling intervention, educational intervention, medical chart review, questionnaire administration, psychosocial assessment and care, quality-of-life assessment
Behavioral · Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2010 · Synced Oct 29, 2026, 5:04 AM EDT
Recruiting Phase 1 Interventional

Trial of THEO-260 (Administered Via Intraperitoneal Route) in Ovarian Cancer Patients

NCT07211659
View directory record Official record
Conditions
Ovarian Cancer
Interventions
THEO-260
Biological
Lead sponsor
Theolytics Limited
Industry
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 29, 2026, 5:04 AM EDT
Completed Phase 2 Interventional

CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer

NCT01652079
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
CRLX101
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
4
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 29, 2026, 5:04 AM EDT
Recruiting Not applicable Interventional

Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy

NCT04997096
View directory record Official record
Conditions
Ovarian Cancer, Ovarian Carcinoma, Ovarian Cancer Stage IV, Ovarian Cancer Stage III, Ovarian Cancer Stage 3, Endometrial Cancer, Endometrial Cancer Stage
Interventions
Exercise, Attention Control
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 29, 2026, 5:04 AM EDT
Completed Phase 3 Interventional Results available

An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy

NCT00191646
View directory record Official record
Conditions
Genital Neoplasms, Female, Fallopian Tube Neoplasms, Ovarian Neoplasms, Pelvic Neoplasms, Peritoneal Neoplasms
Interventions
Gemcitabine, Paclitaxel, Carboplatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
919 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
54
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Gatos, California + 51 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2011 · Synced Oct 29, 2026, 5:04 AM EDT
Terminated Phase 2 Interventional Results available

Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant

NCT00602446
View directory record Official record
Conditions
Breast Cancer, Iron Overload, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer
Interventions
deferasirox
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 29, 2026, 5:04 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib

NCT02873962
View directory record Official record
Conditions
Peritoneal Cancer, Ovarian Cancer, Fallopian Tube Cancer
Interventions
Bevacizumab, Nivolumab, Rucaparib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 29, 2026, 5:04 AM EDT
Active, not recruiting Not applicable Interventional

Onco-primary Care Networking to Support TEAM-based Care

NCT04258813
View directory record Official record
Conditions
Blood Pressure, Hypertension, Cancer, Cancer, Breast, Cancer of Prostate, Cancer Colorectal, Cancer, Endometrial, Cancer of Head and Neck, Non Small Cell Lung Cancer, CVD - Cardiovascular Disease, Diabetes Mellitus, Hypercholesterolemia, Diabetes, Cancer of Esophagus, Cancer of Liver, Cancer, Renal Cell, Cancer of Pancreas, Cancer Ovaries
Interventions
iGuide Intervention (Self-guided), iGuide 2 Intervention (Tailored/Targeted), Control
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 79 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 29, 2026, 5:04 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Polycystic Ovary Syndrome (PCOS) and Sleep Apnea

NCT00203996
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Obstructive Sleep Apnea
Interventions
continuous positive airway pressure (CPAP), depot leuprolide plus estrogen/progestin replacement, pioglitazone, REM frag, SWS supp
Device · Drug · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 40 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 29, 2026, 5:04 AM EDT
Not listed Not applicable Interventional

Assessment of the Sensitivity of the Hypothalamic GnRH Pulse Generator to Estradiol and Progesterone Inhibition

NCT01425541
View directory record Official record
Conditions
Hyperandrogenemia, Polycystic Ovary Syndrome (PCOS)
Interventions
estrace, Progesterone
Drug
Lead sponsor
University of Virginia
Other
Eligibility
8 Years to 18 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 29, 2026, 5:04 AM EDT
Completed Phase 1 Interventional

Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors

NCT03490669
View directory record Official record
Conditions
Advanced Solid Tumors, Pancreatic Cancer, Non Small Cell Lung Cancer, Ovarian Cancer
Interventions
MSC-1
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Scottsdale, Arizona • Grand Rapids, Michigan • Middletown, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2024 · Synced Oct 29, 2026, 5:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Testing a Culturally Adapted Telephone Genetic Counseling Intervention

NCT03959267
View directory record Official record
Conditions
Breast Cancer, Hereditary Breast Cancer
Interventions
Telephone Genetic Counseling
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
21 Years to 90 Years · Female only
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Hackensack, New Jersey • Alexandria, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2021 · Synced Oct 29, 2026, 5:04 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

NCT01081951
View directory record Official record
Conditions
Ovarian Cancer
Interventions
olaparib, paclitaxel, carboplatin, Drug: carboplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 125 Years · Female only
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
8
States / cities
Stanford, California • West Hollywood, California • Orlando, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 29, 2026, 5:04 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Effect of PARP Inhibitors on Glomerular Filtration Rate

NCT04367467
View directory record Official record
Conditions
Solid Tumor, Ovarian Cancer, Breast Cancer
Interventions
Kidney Function Test
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 26, 2022 · Synced Oct 29, 2026, 5:04 AM EDT
Completed Phase 2 Interventional Results available

Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer

NCT01196429
View directory record Official record
Conditions
Ovarian Clear Cell Cystadenocarcinoma, Stage III Ovarian Cancer, Stage IV Ovarian Cancer
Interventions
Carboplatin, Docetaxel, Laboratory Biomarker Analysis, Paclitaxel, Temsirolimus
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
121
States / cities
Phoenix, Arizona • Burbank, California • Los Angeles, California + 82 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2019 · Synced Oct 29, 2026, 5:04 AM EDT
Completed Phase 1 Interventional

Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.

NCT02610075
View directory record Official record
Conditions
Locally Advanced Solid Tumours, Metastatic Solid Tumours, Ovarian Cancer
Interventions
AZD1775
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Scottsdale, Arizona • Denver, Colorado • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 29, 2026, 5:04 AM EDT